Quest to develop laboratory tests and support public health reporting and laboratory readiness for CDC's preparedness strategy; Company to introduce clinical testing for avian flu later this month based on one of the awards SECAUCUS, N.J. , Oct. 23, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been awarded several contracts by the U.S.... Read More

Third quarter revenues of $2.49 billion , up 8.5% from 2023 Third quarter reported diluted earnings per share ("EPS") of $1.99 , up 1.5% from 2023; and adjusted diluted EPS of $2.30 , up 3.6% from 2023 Full year 2024 revenues now expected to be between $9.80 billion and $9.85 billion ; reported diluted EPS now expected to be between $7.60 and $7.70 ; and adjusted diluted EPS expected to be between $8.85 and $8.95 SECAUCUS,... Read More

First-of-its-kind service empowers discreet and more convenient access to testing and treatment for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and Mycoplasma genitalium Self-collection option available at no extra charge at any of Quest's 2,000 patient service centers with a physician's order or through Quest's consumer-initiated test platform at questhealth.com SECAUCUS, N.J.... Read More

Goal to broaden access to cost-effective and innovative laboratory services in Ohio SECAUCUS, N.J. , Oct. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of select laboratory assets from OhioHealth, a nationally recognized not-for-profit, charitable, integrated health system. Financial terms of the... Read More

SECAUCUS, N.J. , Sept. 25, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report third quarter 2024 financial results on Tuesday, October 22, 2024 , before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing... Read More

Quest named exclusive independent lab provider for all Sentara Health Plans in Virginia and Florida SECAUCUS, N.J and HAMPTON ROADS, Va. , Sept. 18, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Sentara Health Plans, the health plan division of Sentara Health, an integrated, not-for-profit health care delivery system, today announced a multi-year... Read More

SECAUCUS, N.J. , Sept. 16, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of select laboratory assets from Allina Health. The goal of the transaction is to improve access to high quality and affordable laboratory services for providers and patients in Minnesota and western Wisconsin . Financial details... Read More

SECAUCUS, N.J. , Aug. 28, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis , Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the Morgan Stanley 22 nd Annual Global Healthcare Conference in New York City on Friday, September 6, 2024 , at... Read More

SECAUCUS, N.J. and TORONTO , Aug. 26, 2024 /CNW/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its acquisition of LifeLabs from OMERS. The transaction, valued at approximately CAN $1.35 billion (approximately USD $1 billion ), including net debt, has received all necessary approvals and is now closed. "This acquisition brings together two industry... Read More

Transaction to broaden access to innovative, quality diagnostic information services powering affordable care in Ohio SECAUCUS, N.J. , and CLEVELAND , Aug. 21, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, and University Hospitals, one of the nation's leading nonprofit health systems and academic medical centers, today announced a definitive agreement for Quest to... Read More

SECAUCUS, N.J. , Aug. 15, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $400 million aggregate principal amount of its 4.600% senior notes due 2027 (the "2027 notes"), $600 million aggregate principal amount of its 4.625% senior notes due 2029 (the "2029 notes") and $850 million aggregate... Read More

Lab tests offer insights for individuals who may experience inadequate intake of essential nutrients due to dietary restrictions, certain prescription medications, or chronic health conditions SECAUCUS, N.J. , Aug. 15, 2024 /PRNewswire/ -- Micronutrients are essential vitamins and minerals that are vital for well-being and disease prevention, but deficiencies can commonly be caused by food allergies and dietary restrictions,... Read More

SECAUCUS, N.J. , Aug. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on October 21, 2024 to shareholders of record of Quest Diagnostics common stock on October 4, 2024. About Quest Diagnostics Quest Diagnostics works across the healthcare ecosystem to create a... Read More

One in three women who tested positive for chlamydia or gonorrhea while pregnant were not retested before giving birth, despite potential to transmit infections to newborns SECAUCUS, N.J. , Aug. 12, 2024 /PRNewswire/ -- A new study by researchers from Quest Diagnostics (NYSE: DGX) and the University of Alabama suggests adherence to guideline-based laboratory testing and treatment of pregnant women for two of the most... Read More

Quest achieves top score of 100 on 2024 Disability Equality Index® Best Places to Work for Disability Inclusion SECAUCUS, N.J. , Aug. 1, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced it has been named to the 2024 Disability Equality Index® Best Places to... Read More

BALTIMORE, Md. and MONTREAL , July 29, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, announced today a research collaboration with Dr. Simon Turcotte , hepatopancreatobiliary surgeon and scientist at Université de Montréal's affiliated hospital research centre, the CRCHUM, to utilize Haystack Oncology's personalized MRD technology (Haystack MRD™) to evaluate treatment effectiveness in... Read More

Second quarter revenues of $2.40 billion , up 2.5% from 2023 Second quarter reported diluted earnings per share ("EPS") of $2.03 , down 1.0% from 2023; and adjusted diluted EPS of $2.35 , up 2.2% from 2023 Full year 2024 revenues now expected to be between $9.50 billion and $9.58 billion ; reported diluted EPS now expected to be between $7.57 and $7.77 ; and adjusted diluted EPS expected to be between $8.80 and $9.00... Read More

Goal to broaden access to cost-effective and innovative laboratory services in Ohio SECAUCUS, N.J. and COLUMBUS, Ohio , July 10, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, and OhioHealth, a nationally recognized not-for-profit, charitable, integrated health system, today announced a definitive agreement for Quest to acquire select assets of OhioHealth's outreach... Read More

SECAUCUS, N.J. and TORONTO , July 3, 2024 /CNW/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a definitive agreement with OMERS to acquire LifeLabs, a trusted provider of community laboratory tests for millions of Canadians, for a value of approximately CAN $1.35 billion (approximately USD $985 million ), including net debt. "Quest has supported laboratories,... Read More

SECAUCUS, N.J. , June 27, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today released its 2023 Corporate Responsibility Report. This year's report provides information on the company's corporate responsibility strategy and environmental, social, and governance (ESG)... Read More

Transaction to broaden access to Quest's innovative and cost-effective services for providers and patients in Minnesota and western Wisconsin SECAUCUS, N.J. and MINNEAPOLIS , June 26, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, and Allina Health, a leading, non-profit health care system, today announced a definitive agreement for Quest to acquire select... Read More

SECAUCUS, N.J. , June 19, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2024 financial results on Tuesday, July 23, 2024 , before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing... Read More

PathAI remains an independent company, focused on developing innovative AI and digital pathology solutions SECAUCUS, N.J. and BOSTON , June 11, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of PathAI Diagnostics from PathAI, with the goal to accelerate the adoption of AI and digital pathology to... Read More

Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are tested for treatment decisions SECAUCUS, N.J. and BALTIMORE , May 31, 2024 /PRNewswire/ -- A blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy... Read More

SECAUCUS, N.J. , May 16, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob) B. Carter , a seasoned technology executive, to serve as a director. Including Mr. Carter, the company's Board has 10 members.... Read More

SECAUCUS, N.J. , May 15, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on July 22, 2024 to shareholders of record of Quest Diagnostics common stock on July 8, 2024. About Quest Diagnostics Quest Diagnostics works across the healthcare ecosystem to create a healthier... Read More

Overall Drug Positivity Holds Steady at Historically High Rates while Marijuana Positivity Continued Upward Climb in the General U.S. Workforce Marijuana Positivity in the General U.S. Workforce Escalated in States That Have Legalized Recreational Marijuana as well as in Professional Office-Based Industries SECAUCUS, N.J. , May 15, 2024 /PRNewswire/ -- The percentage of employees in the general U.S. workforce whose drug test... Read More

SECAUCUS, N.J. , May 7, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis , Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on Wednesday, May 29, 2024 , at 10:20... Read More

SECAUCUS, N.J. , May 6, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technology healthcare business leader, has been named Senior Vice President and Chief Information and Digital Officer (CIDO). Mr.... Read More

Transaction is part of wide-ranging collaboration to combine Quest's oncology expertise and scale with PathAI's AI and digital pathology innovations to speed diagnosis, improve quality and reduce costs SECAUCUS, N.J. and BOSTON , May 1, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology,... Read More

First quarter revenues of $2.37 billion , up 1.5% from 2023 First quarter reported diluted earnings per share ("EPS") of $1.72 , down 3.4% from 2023; and adjusted diluted EPS of $2.04 , flat with 2023 Full year 2024 revenues now expected to be between $9.40 billion and $9.48 billion ; reported diluted EPS now expected to be between $7.57 and $7.82 ; and adjusted diluted EPS expected to be between $8.72 and $8.97 SECAUCUS,... Read More

Company's AD-Detect™ Portfolio Offers AB 42/40 and Other Plasma Biomarker Testing, Alongside Traditional Cerebrospinal Fluid and Genetic Tests, to Provide Robust Offering in Brain Health SECAUCUS, N.J. , April 22, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new blood biomarker test for phosphorylated tau 217, or p-tau217. P-tau217 is a... Read More

Aim to demonstrate whole genome sequencing can replace the standard diagnostic cascade, for potentially faster diagnosis and lower costs SECAUCUS, N.J. , April 2, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Broad Clinical Labs, the world expert in whole genome sequencing (WGS), today announced a research collaboration designed to demonstrate the clinical value of WGS... Read More

Findings suggest the test can reduce the need for PET imaging in some patients with mild cognitive decline to enable therapeutic focus on non-Alzheimer's disease causes, broadening access to quality evaluation and lowering healthcare costs SECAUCUS, N.J. , March 26, 2024 /PRNewswire/ -- A blood test that analyzes levels of amyloid proteins by highly sensitive mass spectrometry could help physicians establish that Alzheimer's... Read More

SECAUCUS, N.J. , March 19, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2024 financial results on Tuesday, April 23, 2024 , before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing... Read More

SECAUCUS, N.J. , Feb. 23, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad , Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the Barclays 26 th Annual Global Healthcare Conference in Miami on Wednesday, March 13,... Read More

Grocery Delivery Services Now Available via Instacart to Individuals Participating in the Coaching Programs of Pack Health, a Quest Diagnostics Company, to Mitigate Social Determinants of Health Impacting Care BIRMINGHAM, Ala. and SAN FRANCISCO , Feb. 21, 2024 /PRNewswire/ -- Pack Health , a Quest Diagnostics (NYSE: DGX) company specializing in patient engagement, and Instacart (NASDAQ: CART), the leading grocery technology... Read More

Roche led the financing alongside existing and new investors The funds will progress clinical programs and expand platform capabilities SOUTH SAN FRANCISCO, Calif. , Feb. 15, 2024 /PRNewswire/ -- Freenome, a biotechnology company developing blood tests for early cancer detection, announced the addition of $254 million from new and existing investors. The funding enables Freenome to advance the pipeline of single-cancer and... Read More

Based on technology from SkylineDx, the test aims to aid treatment decisions for patients with the deadliest form of skin cancer Patients classified as low-risk by MelaNodal Predict are shown to have survival rate of over 90 percent SECAUCUS, N.J. , and SAN DIEGO , Feb. 13, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced the launch of... Read More

Directed at individuals who may be at risk of elevated PFAS exposure, the new test detects and measures PFAS identified by National Academies of Sciences, Engineering, and Medicine Organizations interested in workforce, community, and research population testing may also access the test SECAUCUS, N.J. , Feb. 12, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leader in diagnostic information services, today... Read More

Fourth quarter revenues of $2.29 billion , down 1.9% from 2022 Fourth quarter reported diluted earnings per share ("EPS") of $1.70 , up 95.4% from 2022; and adjusted diluted EPS of $2.15 , up 8.6% from 2022 Fourth quarter base business revenues of $2.25 billion , up 4.7% from 2022 Fourth quarter COVID-19 testing revenues of $37 million , down 79.8% from 2022 Full year revenues of $9.25 billion , down 6.4% from 2022 Full year... Read More

SECAUCUS, N.J. , Jan. 31, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2024 for the tenth consecutive year. Fortune's World's Most Admired Companies recognition is based on nine criteria of corporate reputation, from innovation and quality of management and... Read More

BALTIMORE , Jan. 22, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD™), has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9)... Read More

SECAUCUS, N.J. , Jan. 17, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2023 financial results on Thursday, February 1, 2024 , before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference... Read More

Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J. , Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which... Read More

Goal to combine Ultima’s highly sensitive, low-cost technology with Quest’s oncology expertise and national scale in order to improve patient access, affordability and outcomes FREMONT, Calif & SECAUCUS, N.J. / Jan 09, 2024 / Business Wire / Ultima Genomics , a developer of a revolutionary new ultra-high throughput sequencing architecture, and Quest Diagnostics (NYSE: DGX), the nation’s leading provider of diagnostic... Read More

Transaction to broaden access to innovative, quality diagnostic information services for providers and patients SECAUCUS, N.J. , Jan. 8, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has acquired select assets of Steward Health Care System's outreach laboratory services business serving patients and physicians in Pennsylvania and Ohio.... Read More

BALTIMORE , Jan. 8, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology's personalized MRD technology (Haystack MRD™) to analyze therapeutic response and provide molecular insights for AFT's interventional, randomized phase II clinical trial (AFT-57) in patients with unresectable... Read More

SECAUCUS, N.J. , Dec. 21, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that Jim Davis , Chairman, CEO and President, and Sam Samad , Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance, and the latest market developments and trends during a fireside chat at the 42 nd Annual J.P.... Read More

Seasoned healthcare executive and oncologist joins Executive Leadership Team SECAUCUS, N.J. , Dec. 20, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that Yuri A. Fesko , M.D., has been named senior vice president and chief medical officer (CMO), effective immediately. Dr. Fesko is a seasoned healthcare executive with deep experience in... Read More

Xylazine found in 1 in 12 specimens tested, finds new 'Drug Misuse in America' Health Trends® report on the rising polysubstance crisis SECAUCUS, N.J. , Dec. 19, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a... Read More

BALTIMORE , Dec. 14, 2023 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Rutgers Cancer Institute of New Jersey to use Haystack Oncology's industry-leading personalized MRD technology (Haystack MRD™) to help evaluate therapeutic response and provide molecular insights for a Rutgers Cancer Institute clinical trial examining early-stage triple-negative breast... Read More

Quest will provide research consulting, laboratory testing and data analytics services to generate diagnostics insights supporting population health strategy for hepatitis C SECAUCUS, N.J. , Dec. 7, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that it has been awarded a contract by the United States Centers for Disease Control and... Read More

SECAUCUS, N.J. , Dec. 6, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that for the seventh straight year it has received a score of 100% on the Human Rights Campaign Foundation's 2022-2024 Corporate Equality Index (CEI) , the nation's foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ+... Read More

Relationship leverages Quest's sequencing and specimen collection expertise with Scipher's precision medicine technology SECAUCUS, N.J. and WALTHAM, Mass. , Nov. 28, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Scipher Medicine, a precision immunology company, today announced a multi-pronged collaboration designed to expand patient access to... Read More

UDX also announces the initial closing of its series B financing of approximately $70 million with investors, including Quest Diagnostics Financing to support UDX's pursuit of FDA premarket approval for its colorectal cancer screening blood test CAMBRDIGE, Mass. and SECAUCUS, N.J. , Nov. 20, 2023 /PRNewswire/ -- Universal DX (" UDX" ), a biotech company on a mission to transform cancer into a curable disease, today announced... Read More

SECAUCUS, N.J. , Nov. 13, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.71 per share, payable on January 31, 2024 to shareholders of record of Quest Diagnostics common stock on January 17, 2024 . About Quest Diagnostics Quest Diagnostics empowers people to take action to... Read More

Quest Mobile™ has 5,000 trained mobile phlebotomists whose reach will extend to 44 states by the end of 2023 SECAUCUS, N.J. , Nov. 9, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced the launch of Quest Mobile™, which makes it easier and more convenient for patients to have a specimen collected for lab testing nationwide. Patients can... Read More

SECAUCUS, N.J. , Oct. 30, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the pricing of a public offering of $750 million aggregate principal amount of its 6.400% senior notes due 2033 under Quest Diagnostics' shelf registration statement. Quest Diagnostics expects to receive the net offering proceeds upon closing on November... Read More

Quest to Develop and Market a Lab-developed Test Based on the IP of AlzoSure Predict ® in the United States , Extending its Industry-leading Portfolio of Alzheimer's Disease Blood Tests Validating Clinical Data Suggests that AlzoSure ® Predict's Blood-Based Technology Can Help Identify Whether or Not Individuals Will Progress to Alzheimer's Disease Up to 6 Years Before Diagnosis MILAN and SECAUCUS, N.J. , Oct. 25, 2023... Read More

Third quarter revenues of $2.30 billion , down 7.7% from 2022 Third quarter reported diluted earnings per share ("EPS") of $1.96 , down 9.7% from 2022; and adjusted diluted EPS of $2.22 , down 5.9% from 2022 Third quarter base business revenues of $2.27 billion , up 4.6% from 2022 Full year 2023 revenues now expected to be between $9.19 billion and $9.24 billion ; reported diluted EPS now expected to be between $7.61 and... Read More

Relationship features use of Quest's distributed network of labs to deliver fast testing times in local communities around the United States LITTLETON, Colo. , Oct. 5, 2023 /PRNewswire/ -- Neway, LLC, the U.S. leader in value-based dialysis lab care, today announced a strategic lab services arrangement with Quest Diagnostics (NYSE: DGX) that aims to accelerate dialysis laboratory testing and reduce the laboratory costs of... Read More

SECAUCUS, N.J. , Oct. 4, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2023 financial results on Tuesday, October 24, 2023 , before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed... Read More

SECAUCUS, N.J. , Sept. 8, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that Sam Samad , Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the Baird 2023 Global Healthcare Conference in New York City on... Read More

SECAUCUS, N.J. , Sept. 7, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leader in diagnostic information services, today released its 2022 Corporate Responsibility Report. The report provides information on the company's strategy regarding environmental, social, and governance (ESG) issues which aligns with The Quest... Read More

Quest and Sarepta Therapeutics Expand Collaboration to Develop AAV Companion Diagnostics (CDx) for Sarepta's Gene Therapies SECAUCUS, N.J. and CAMBRIDGE, Mass. , Aug. 30, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that its AAVrh74 ELISA assay (CDx) has been granted Breakthrough Device Designation from the U.S. Food and Drug... Read More

SECAUCUS, N.J. , Aug. 14, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.71 per share, payable on October 23, 2023 to shareholders of record of Quest Diagnostics common stock on October 6, 2023. About Quest Diagnostics Quest Diagnostics empowers people to take action to... Read More

Ten-fold increase in death risk in individuals with high levels of myeloperoxidase, or MPO, compared to those with low levels, according to analysis of 3,700 patients of MDVIP tested by Quest Diagnostics SECAUCUS, N.J. , and BOCA RATON, Fla. , Aug. 2, 2023 /PRNewswire/ -- The higher the level of a marker of inflammation in circulating blood, the greater the risk of dying from a range of medical disorders, according to a new... Read More

AD-Detect ™ Test for Alzheimer's Disease is the first blood-based biomarker test for assessing beta amyloid protein, a recognized marker of Alzheimer's disease, available for consumer purchase to help individuals identify their risk of developing Alzheimer's disease Physician oversight included in offering, helping individuals interpret results and determine next steps SECAUCUS, N.J. , July 31, 2023 /PRNewswire/ -- Quest... Read More

Second quarter revenues of $2.34 billion , down 4.7% from 2022 Second quarter reported diluted earnings per share ("EPS") of $2.05 , up 4.6% from 2022; and adjusted diluted EPS of $2.30 , down 2.5% from 2022 Second quarter base business revenues of $2.30 billion , up 9.5% from 2022 Full year 2023 revenues now expected to be between $9.12 billion and $9.22 billion ; reported diluted EPS now expected to be between $7.52 and... Read More

Lab service utilizes Envision Science's proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer SECAUCUS, N.J. and MELBOURNE, Australia , July 13, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services, today announced the launch of a novel prostate cancer biomarker test through its subspecialty pathology business, AmeriPath,... Read More

SECAUCUS, N.J. , July 13, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced it has been named to the 2023 Disability Equality Index ® (DEI) Best Places to Work for Disability Inclusion by Disability: IN and the American Association of People with Disabilities (AAPD). The Disability Equality Index (DEI) is a comprehensive benchmarking tool that helps... Read More

First consumer genetic health test under the Quest brand provides insights based on DNA, with unique features that include next-generation sequencing, robust support services, physician ordering, and access to one-on-one genetic counseling SECAUCUS, N.J. , July 11, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leader... Read More

Organized by nine laboratories on five continents, the study by some members of the Global Diagnostics Network, a Quest Diagnostics-led strategic working group, is the largest to evaluate worldwide variability in cholesterol and triglyceride test results People tested in seven of 17 countries had total cholesterol results signifying heightened cardiovascular disease risk relative to the World Health Organization target... Read More

First and only FDA-cleared PdG (progesterone metabolite) home test to help confirm successful ovulation SECAUCUS, N.J. , July 6, 2023 /PRNewswire/ -- Women seeking to start or expand a family can now access the Proov Confirm PdG home collection kit for assessing fertility through questhealth.com . Available through a collaboration with the consumer-initiated testing business of Quest Diagnostics (NYSE: DGX) and Proov, maker... Read More

SECAUCUS, N.J. , June 21, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2023 financial results on Wednesday, July 26, 2023 , before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be... Read More

SECAUCUS, N.J. , June 21, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, today announced that it has completed its previously announced acquisition of Haystack Oncology. Haystack Oncology has developed a highly sensitive minimal-residual disease (MRD) testing technology, based on circulating tumor DNA (ctDNA), to aid in the early detection of residual or... Read More

SECAUCUS, N.J. , June 2, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Jefferies Global Healthcare Conference. Jim Davis , Chairman, CEO and President, will discuss recent market developments and trends as well as the company's performance and strategy. The presentation is scheduled for Thursday,... Read More

SECAUCUS, N.J. , June 1, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the William Blair 43rd Annual Growth Stock Conference. Sam Samad , Executive Vice President and CFO will discuss recent market developments and trends as well as the company's performance and strategy. The presentation is... Read More

Increase Seen in the General U.S. Workforce Started Same Year First States Legalized Recreational Marijuana Overall Workforce Drug Test Positivity Persisted at Two-Decade High Across All Workers Marijuana and Amphetamines Positivity Climbed in Key Industries SECAUCUS, N.J. , May 18, 2023 /PRNewswire/ -- The percentage of... Read More

SECAUCUS, N.J. , May 17, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Luis A. Diaz, Jr. , M.D. to serve as a director. Including Dr. Diaz, the company's Board has 10 members. Dr. Diaz, 52, has been Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center since December... Read More

SECAUCUS, N.J. , May 16, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.71 per share, payable on July 25, 2023 to shareholders of record of Quest Diagnostics common stock on July 11, 2023. About Quest Diagnostics Quest Diagnostics empowers people to take action to improve... Read More

The collaboration aims to help physicians improve detection and care of potentially treatable causes of cognitive decline SECAUCUS, N.J. and RALEIGH, N.C. , May 4, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced nationwide availability of the RestoreU ™ Dementia Panel, a risk assessment and care plan service created by uMETHOD Health, a... Read More

First quarter revenues of $2.33 billion , down 10.7% from 2022 First quarter reported diluted earnings per share ("EPS") of $1.78 , down 39.0% from 2022; and adjusted diluted EPS of $2.04 , down 36.6% from 2022 First quarter base business revenues of $2.21 billion , up 10.0% from 2022 Full year 2023 revenues now expected to be between $8.93 billion and $9.08 billion ; reported diluted EPS now expected to be between $7.52 and... Read More

Goal to improve patient outcomes through early, accurate detection of residual or recurring cancer Haystack's highly sensitive minimal-residual disease cancer-detection technology to be combined with Quest's oncology, genomics and pathology expertise and scale, including solid tumor sequencing, convenient specimen collection and EHR connectivity SECAUCUS, N.J. and BALTIMORE , April 27, 2023 /PRNewswire/ -- Quest Diagnostics... Read More

SECAUCUS, N.J. , April 17, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, and NewYork-Presbyterian, one of the nation's largest and most comprehensive academic medical centers, today announced that Quest has completed its previously announced acquisition of select assets of the laboratory services business of NewYork-Presbyterian. Financial details of the... Read More

SECAUCUS, N.J. , April 4, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2023 financial results on Thursday, April 27, 2023 , before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed... Read More

New capabilities include personalized patient access to Quest's national network of 2,100 patient service centers and 5 ,000 mobile and at-home phlebotomists, to support patient-compliant pre- and post-transplant testing and nationwide access, regardless of surgical center location SECAUCUS, N.J. , March 22, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services,... Read More

New Panels Aimed at the Millions of Americans Still Suffering From COVID-19 Side Effects SECAUCUS, N.J. , March 21, 2023 /PRNewswire/ -- The consumer-initiated testing business from the leader in diagnostic testing, Quest Diagnostics (NYSE: DGX), has introduced two innovative Post-COVID-19 panels. These laboratory tests are the only comprehensive tests currently available for consumers to purchase that offer information... Read More

SECAUCUS, N.J. , March 20, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of select assets of Northern Light Laboratory, the outreach laboratory services business of Northern Light Health, a large integrated healthcare system in Maine . The collaboration between the two parties is... Read More

Updates 2023-26 compound annual growth rate (CAGR): Revenues expected to grow at mid single-digit rate; adjusted diluted earnings per share (EPS)* expected to grow at high single-digit rate Recommits to Invigorate savings and productivity improvements of approximately 3% annually Guidance for 2023 provided on February 2, 2023 remains unchanged SECAUCUS, N.J. , March 16, 2023 /PRNewswire/ -- At a meeting with analysts and... Read More

SECAUCUS, N.J. , March 3, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis , the company's Chief Executive Officer and President, to serve in the additional position of Chairman of the Board of Directors, effective April 1, 2023 . "The Board carefully considered our governance structure and... Read More

SECAUCUS, N.J. , Jan. 20, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2022 financial results on Thursday, February 2, 2023 , before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference... Read More

Marks 1 -Year since Quest Diagnostics Announced Plans to Acquire Pack Health to Extend Digital Engagement and Coaching Services to Health Plans, Employers and Life Sciences Companies BIRMINGHAM, Ala. , Jan. 17, 2023 /PRNewswire/ -- Leading patient engagement company Pack Health , a Quest Diagnostics (NYSE: DGX) company, today announced plans to nearly double the space of its headquarter facilities in Birmingham and add at... Read More

NORTHAMPTON, MA / ACCESSWIRE / January 5, 2023 / Quest Diagnostics It's difficult to overestimate the toll that the COVID-19 pandemic has had on many of our nation's children-academically, socially, developmentally, and emotionally. Quest Diagnostics recognizes the critical role that daily in-school learning plays in helping... Read More

NORTHAMPTON, MA / ACCESSWIRE / January 4, 2023 / Glenn Family Foundation , a nonprofit whose mission is to improve life outcomes for children, youth, and families in the Mississippi Delta by erasing health inequities, recently hosted its 8th annual I-HEAL Community Wellness Day. The event provides community members with... Read More

SECAUCUS, N.J. , Jan. 4, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 41st Annual J.P. Morgan Healthcare Conference. Jim Davis , CEO and President, and Sam Samad , Executive Vice President and CFO, will discuss the company's performance, and strategy, and the latest market developments and... Read More

NORTHAMPTON, MA / ACCESSWIRE / December 28, 2022 / Quest Diagnostics "As a leader in the nation's COVID-19 testing response, Quest Diagnostics is continually spearheading new innovations to broaden access to quality COVID-19 diagnostic insights. - Cathy Doherty Senior Vice President, Regional Businesses In response to the ongoing COVID-19 public health emergency, Quest added numerous COVID-19 tests to its menu in record... Read More

NORTHAMPTON, MA / ACCESSWIRE / December 20, 2022 / Quest Diagnostics : Presbyterian Medical Services (PMS) is an FQHC that delivers integrated healthcare, education, and services to address the needs of diverse communities across the Southwest, with a specific focus on Native American populations. PMS serves more than 9,000... Read More

NORTHAMPTON, MA / ACCESSWIRE / December 14, 2022 / Quest Diagnostics "As an Olympian and as a breast cancer survivor, I've learned the importance of following my intuition. If you have a family history of cancer, trust your instincts. Get answers for yourself with hereditary cancer screenings and genetic testing." Chaunté... Read More